The Divide Between Eli Lilly and Novo Nordisk Widens After Latest Earnings The earnings reports from Eli Lilly and Novo Nordisk this week highlighted a growing chasm between these two pharmaceutical giants in the GLP 1 market.
While investors celebrated Lilly's continued dominance, they punished Novo with a lackluster response, underscoring concerns about the Danish company's ability to match its American counterpart.
Lilly's success is particularly striking, with the company now holding a 60. 9% share of the US obesity and diabetes drug market, leaving Novo with a mere 38. 8%.